spacer
spacer

PDBsum entry 4f57

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Immune system PDB id
4f57

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
213 a.a.
225 a.a.
Ligands
GOL
Waters ×532
PDB id:
4f57
Name: Immune system
Title: Fab structure of a neutralizing antibody l1 from an early subtype a HIV-1 infected patient
Structure: Light chain of fab of a neutralizing antibody l1. Chain: l. Fragment: light chain of l1. Heavy chain of fab of a neutralizing antibody l1. Chain: h. Fragment: heavy chain of l1
Source: Homo sapiens. Human. Organism_taxid: 9606. Organism_taxid: 9606
Resolution:
1.70Å     R-factor:   0.188     R-free:   0.209
Authors: R.M.Pan,X.P.Kong
Key ref: M.K.Murphy et al. (2013). Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog, 9, e1003173. PubMed id: 23468623
Date:
12-May-12     Release date:   27-Mar-13    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
No UniProt id for this chain
Struc: 213 a.a.
Protein chain
No UniProt id for this chain
Struc: 225 a.a.
Key:    Secondary structure  CATH domain

 

 
PLoS Pathog 9:e1003173 (2013)
PubMed id: 23468623  
 
 
Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.
M.K.Murphy, L.Yue, R.Pan, S.Boliar, A.Sethi, J.Tian, K.Pfafferot, E.Karita, S.A.Allen, E.Cormier, P.A.Goepfert, P.Borrow, J.E.Robinson, S.Gnanakaran, E.Hunter, X.P.Kong, C.A.Derdeyn.
 
  ABSTRACT  
 
Antibodies that neutralize (nAbs) genetically diverse HIV-1 strains have been recovered from a subset of HIV-1 infected subjects during chronic infection. Exact mechanisms that expand the otherwise narrow neutralization capacity observed during early infection are, however, currently undefined. Here we characterized the earliest nAb responses in a subtype A HIV-1 infected Rwandan seroconverter who later developed moderate cross-clade nAb breadth, using (i) envelope (Env) glycoproteins from the transmitted/founder virus and twenty longitudinal nAb escape variants, (ii) longitudinal autologous plasma, and (iii) autologous monoclonal antibodies (mAbs). Initially, nAbs targeted a single region of gp120, which flanked the V3 domain and involved the alpha2 helix. A single amino acid change at one of three positions in this region conferred early escape. One immunoglobulin heavy chain and two light chains recovered from autologous B cells comprised two mAbs, 19.3H-L1 and 19.3H-L3, which neutralized the founder Env along with one or three of the early escape variants carrying these mutations, respectively. Neither mAb neutralized later nAb escape or heterologous Envs. Crystal structures of the antigen-binding fragments (Fabs) revealed flat epitope contact surfaces, where minimal light chain mutation in 19.3H-L3 allowed for additional antigenic interactions. Resistance to mAb neutralization arose in later Envs through alteration of two glycans spatially adjacent to the initial escape signatures. The cross-neutralizing nAbs that ultimately developed failed to target any of the defined V3-proximal changes generated during the first year of infection in this subject. Our data demonstrate that this subject's first recognized nAb epitope elicited strain-specific mAbs, which incrementally acquired autologous breadth, and directed later B cell responses to target distinct portions of Env. This immune re-focusing could have triggered the evolution of cross-clade antibodies and suggests that exposure to a specific sequence of immune escape variants might promote broad humoral responses during HIV-1 infection.
 

 

spacer

spacer